Forbes

2 Million Patients And Beyond: Abbott’s FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
Monthly Prescribing Reference

FreeStyle Libre 2 Cleared for Use in Adults and Pediatric Patients With Diabetes

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...
Nasdaq

Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms

- FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms1 to alert users when their glucose is high or low without scanning - Now for ...
MobiHealthNews

Abbott's FreeStyle Libre 2 CGM picks up Medicare coverage

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...
FOX31 Denver

U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...
It News Online

Abbott Launches Next-Gen FreeStyle Libre® 2 Plus with Continuous Glucose Readings Every Minute & Optional Alarms

Abbott, the global healthcare company, today announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott’s latest addition to the FreeStyle Libre sensor portfolio. This innovative device offers ...